Calcipotriol
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Calcipotriol: From Psoriasis to Seborrheic Keratosis
One-Sentence Summary
Calcipotriol is a synthetic Vitamin D3 analogue (VDR agonist) widely used as a topical treatment for plaque psoriasis. The TxGNN model predicts it may be effective for Seborrheic Keratosis, with 0 clinical trials and 6 publications currently supporting this direction. The mechanistic rationale is well-grounded, and short-term clinical case series show promising complete remission rates.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Plaque psoriasis (topical treatment) |
| Predicted New Indication | Seborrheic Keratosis |
| TxGNN Prediction Score | 99.96% |
| Evidence Level | L3 |
| Singapore Market Status | Not marketed (0 registrations) |
| Number of Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Calcipotriol is a synthetic Vitamin D3 analogue that binds and activates the Vitamin D Receptor (VDR). Through VDR activation, calcipotriol downregulates cyclin D1 and upregulates the cell-cycle inhibitors p21 and p27, suppressing keratinocyte proliferation. It also induces apoptosis in abnormal keratinocytes via the Bax/Bcl-2 pathway — a mechanism directly demonstrated in clinical studies of topical vitamin D3 analogues applied to seborrheic keratosis lesions (PMID 16043912).
Seborrheic keratosis is characterised by benign, slow-growing epidermal hyperproliferation — pathologically analogous to the dysregulated keratinocyte turnover seen in psoriasis, calcipotriol's established indication. Unlike malignant tumours, benign keratotic lesions tend to be more responsive to VDR-mediated anti-proliferative signalling, making the mechanistic extension biologically sound. The topical route of administration is identical for both conditions, eliminating formulation compatibility concerns.
Multiple clinical case series have reported complete regression of seborrheic keratoses following topical 0.005% calcipotriol application over 3–8 months, with sustained remission lasting 6–10 years (PMID 36752725). A larger clinical study of 116 cases treated with active vitamin D3 analogues including calcipotriol showed a 30.2% complete response rate (PMID 16043912). This positions calcipotriol as a potentially viable non-invasive alternative to the standard cryosurgical approach, particularly for cosmetically sensitive facial lesions.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 36752725 | 2023 | Prospective Clinical Study | Australasian Journal of Dermatology | 12 patients with facial seborrheic keratosis treated with 0.005% calcipotriol ointment; complete regression in all cases after 3–8 months; remission sustained for 6–10 years |
| 16043912 | 2005 | Clinical Study | The Journal of Dermatology | 116 seborrheic keratosis cases treated with topical vitamin D3 analogues (tacalcitol, calcipotriol, maxacalcitol); 30.2% complete response rate; proposed mechanism is VDR-induced apoptosis |
| 15577148 | 2004 | Clinical Study / Case Series | Clinical Calcium | Active vitamin D3 ointments including calcipotriol applied once or twice daily showed effectiveness against senile warts (seborrheic keratosis) in elderly patients |
| 15090020 | 2004 | Comparative Controlled Study | International Journal of Dermatology | Compared standard cryosurgery versus topical calcipotriene, tazarotene, and imiquimod in seborrheic keratoses; assessing patient preference for topical alternatives |
| 10721662 | 2000 | Case Report | The Journal of Dermatology | Patient with keratosis lichenoides chronica (a keratotic dermatosis with seborrheic dermatitis-like features) showed marked clinical response to calcipotriol ointment |
| 21534378 | 2011 | Case Report | JAAPA | Clinical vignette describing seborrheic keratosis presentation and differential diagnosis considerations |
Singapore Market Information
Calcipotriol is not currently registered with the Health Sciences Authority (HSA) in Singapore. No market authorisations are on record.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Multiple clinical studies — including a prospective case series demonstrating complete regression with up to 10-year follow-up — support the topical use of calcipotriol for seborrheic keratosis via a mechanistically well-grounded VDR-mediated anti-proliferative pathway. The evidence base reaches L3, which is sufficient to justify formal feasibility planning, provided that missing safety data and regulatory gaps are resolved before clinical use.
To proceed, the following is needed:
- Obtain and review the full safety profile: package insert warnings, contraindications, and drug interactions (TFDA/international label)
- Confirm the import/registration pathway for calcipotriol with HSA, as there are currently no Singapore-registered products
- Retrieve detailed mechanism of action data from DrugBank to complete the pharmacological assessment
- Commission or identify a prospective randomised controlled trial comparing calcipotriol against standard cryotherapy to establish Level 1–2 evidence
- Conduct a pharmacokinetic safety assessment of percutaneous absorption from keratotic skin and evaluate risk of hypercalcaemia with prolonged topical use over large surface areas
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.